anizome.cotswoldweb.co.uk Open in urlscan Pro
138.68.169.40  Public Scan

Form analysis
1 forms found in the DOM

Name: wf-form-Email-Form — POST https://www.createsend.com/t/subscribeerror?description=

<form id="wf-form-Email-Form" name="wf-form-Email-Form" data-name="Email Form" method="post" action="https://www.createsend.com/t/subscribeerror?description="
  data-id="A61C50BEC994754B1D79C5819EC1255C6EC28BFC666E5D602AD46C675FD85B0D7FA92FB216F09FC6024652BD9BCA1F5B64A1729A40A500C2E11260F946996A3C" class="js-cm-form">
  <div class="form-item first-form-item"><label for="cm-name" class="form-label">Name *</label><input type="text" id="cm-name" name="cm-name" data-name="cm-name" maxlength="256" required="" class="form-field w-input"></div>
  <div class="form-item"><label for="cm-f-jtlktui" class="form-label">Company name *</label><input type="text" id="fieldjtlktui" name="cm-f-jtlktui" data-name="cm-f-jtlktui" maxlength="256" required="" class="form-field w-input"></div>
  <div class="form-item"><label for="cm-gehjy-gehjy" class="form-label">Email address *</label><input type="email" id="fieldEmail" name="cm-gehjy-gehjy" data-name="cm-gehjy-gehjy" required="" maxlength="256"
      class="form-field js-cm-email-input w-input"></div>
  <div class="form-item"><label for="cm-f-jtlktuk" class="form-label">Phone number</label><input type="text" id="fieldjtlktuk" name="cm-f-jtlktuk" data-name="cm-f-jtlktuk" maxlength="256" class="form-field w-input"></div>
  <div class="form-item"><label for="cm-f-jtlktuu" class="form-label">Enquiry details *</label><textarea id="fieldjtlktuu" name="cm-f-jtlktuu" data-name="cm-f-jtlktuu" maxlength="5000" required="" class="form-field text-area w-input"></textarea>
  </div>
  <div class="form-item"><input type="submit" value="Send Message" data-wait="Please wait..." class="hollow-button contact-button js-cm-submit-button w-button"></div>
  <div class="w-embed w-script">
    <script type="text/javascript" src="https://js.createsend1.com/javascript/copypastesubscribeformlogic.js"></script>
  </div>
</form>

Text Content

Text Link
HomeAboutTechnologyPipelineServiceTeamPartnerNewsContact



Animal microbiome innovation for
next-generation veterinary health solutions

TECHNOLOGY PLATFORM




THE MICROBIOME PLAYS A CRUCIAL ROLE IN ANIMAL HEALTH

The microbiome is the collection of billions of microorganisms that live in and
on the bodies of both humans and animals. These unique communities play a vital
role in maintaining health and protecting their host against disease.

Biomedical research in the human microbiome has already led to a pipeline of
therapeutic candidates for the treatment of important diseases such as
inflammatory bowel disease, obesity, and cancer — all of which pose a similar
threat in our growing, aging pet population.

Discovering the importance of a diverse gut microbiome in maintaining good
health is forcing us to rethink the way we treat disease in livestock,
incorporating the microbiome as a promising way of optimizing performance
without antibiotic intervention.




UNLOCKING THE THERAPEUTIC POTENTIAL
OF THE MICROBIOME IN ANIMALS

ANIZOME is dedicated to improving animal health by translating cutting-edge
research and discovery into innovative therapeutic solutions, capable of
optimizing performance and preventing disease.


ABOUT ANIZOME

ANIZOME LLC was founded in 2018 as a result of a ground-breaking venture between
Baylor College of Medicine, Stonehaven Consulting AG and Diversigen Inc. This
unique combination of microbiome expertise, industry knowledge and commercial
experience has enabled ANIZOME to establish a world-class animal microbiome
platform that bridges the gap between research and commercial solutions.

Located in the Texas Medical Centre, the world’s largest health science complex,
ANIZOME’s experienced team of experts are building on more than a decade of
breakthrough discovery in the microbiome to develop next generation solutions
for both farm and companion animals.


FOUNDERS

The power of the microbiome is derived from the unique combination of
microorganisms working in harmony to transform host health. Similarly, ANIZOME’s
founders have formed an alliance to advance a shared cause, creating a unique
ecosystem of expertise capable of revolutionizing the way we treat animal
disease.


BAYLOR COLLEGE OF MEDICINE

Baylor College of Medicine (BCM) is a premier health sciences university in the
United States. A partner in the Human Microbiome Project, BCM is home to
pioneering microbiome science in the Alkek Center for Metagenomics and
Microbiome Research, the Department of Molecular Virology and Microbiology and
Texas Children’s® Microbiome Center.


STONEHAVEN INCUBATE

Stonehaven Incubate AG is a member of the Stonehaven group of companies.
Stonehaven Incubate’s mission is to identify disruptive technologies in human
health and work collaboratively with the technology originator to build a
strategy for a new stand-alone animal health company, identify an experienced
management team and source the capital required.


DIVERSIGEN

Diversigen Inc. is a leading human microbiome company providing end-to-end
solutions for pharma. These include sequencing, bioinformatics, and complex
statistical analyses. Diversigen operates a state-of-the-art CLIA/CAP laboratory
deploying a variety of techniques on many sample types for subsequent
metagenomics analysis and leverages proprietary cohorts and data sets to enable
microbiome therapeutic discoveries.

Meet The Team


TECHNOLOGY PLATFORM

ANIZOME’s unique microbiome platform is underpinned by innovative technology and
expert insight to generate creative breakthroughs in the animal microbiome. The
platform consolidates state-of-the-art technologies inside a single, structured
research and development process focused on generating commercial solutions.


END-TO-END CAPABILITIES

The microbiome is a complex community of bacteria, fungi, archaea and viruses.
Unravelling the functionality and harnessing the power of the microbiome
requires a multidisciplinary, end-to-end scientific approach. Our platform
incorporates innovative technology that enables us to fully characterize the
microbiome, cultivate targets of interest and test them in high-throughput
biological models.

‍Click on the Icons to learn more…






DNA SEQUENCING

ANIZOME utilizes state-of-the-art DNA sequencing technology to achieve fast,
accurate, and complete microbiome analysis utilizing samples obtained from oral,
skin, and intestinal microbiomes. Our technology ranges from identification of
important microbiome population taxonomy trends using 16s sequencing; to
understanding functions, relationships, and importance of individual bacteria
within the entire microbiome using next-generation WGS techniques under CLIA/CAP
accredited lab conditions.






DATA SCIENCE

ANIZOME uses world-class bioinformatics and bioanalytic capabilities to fully
characterize microbiome populations, trends, and individual functions to
discover novel mechanisms, generate leads, and assess the impact of
interventions. ANIZOME is focused on good data science and expert statistical
analysis to guarantee accurate results.






MOLECULAR ANALYSIS

ANIZOME can rapidly and efficiently produce a wide variety of microbiome and
bacterial probing tools for rapid identification of key bacterial, fungal, or
viral species present in the microbiome as well as associated activity
mechanisms. This supports discovery and the development of accurate diagnostic
tools.






BACTERIAL CULTIVATION

ANIZOME can cultivate complex microbial communities and individual bacteria,
including aerobic and anaerobic strains in high-throughput and high replication.
This enables us to develop a bank of strains which are important for maintaining
proper function or inhibiting disease.






MICROBIOME ENGINEERING

From selection and refinement of therapeutic probiotics to engineering of
bacteriophage, ANIZOME can explore various mechanisms for manipulating the
microbiome. For example, we can deploy highly specialized and effective
technology for the identification, selection, and evolution of bacteriophages
against targeted bacterial species in the microbiome. Using this technology
results in the rapid discovery and development of microbiome editing tools.






BIOLOGICAL MODELING

ANIZOME uses various biological models to identify the microbial influence on
host health, rapidly test hypothesis and generate proof of concept.


‍MiniBioReactor Arrays (MBRAs): Cultivating mock intestinal communities for
target animals to recapitulate functions they create in the host.

‍‍C. elegans: Utilizing nematodes as a simple model organism to identify the
genetics of microbial manipulation of host health and metabolites involved.

‍Germ-free rodents: The optimal standard for testing microbiome-host
interactions and pre-clinical performance of microbiome-based products.









Partner With Us


PIPELINE

Our pipeline is focused on delivering a novel class of therapeutic, derived from
health-giving microbes and bacteriophages to manipulate the microbiome and
improve host health. Our broad portfolio of research and development programs
cover some of the most serious health challenges facing both farm and companion
animals.

 * Screening
   Correlate the microbiome with disease / hunt for known mechanisms.
 * Discovery
   Pinpoint causality and identify mechanisms for preventing disease.
 * Lead Optimisation
   Select and engineer appropriate microbiome modulators.
 * Pre-Clinical
   Demonstrate proof of concept in biological models.
 * Clinical
   Generate safety and efficacy data in target animal to support registration.

Partner With Us


SERVICE

In partnership with our sister company, Diversigen Inc., we offer specialist
metagenomic sequencing services tailored to animal microbiome samples and
analysis.

For more information about our metagenomic sequencing services, please contact
us at info@anizome.com


MANAGEMENT TEAM

Oliver Hardcastle

Chief Executive Officer

Former life science business consultant with industry experience in animal
health.Read more


Mr. Oliver Hardcastle has global experience in the pharmaceutical sector. He
previously worked for Novartis, holding a broad range of positions in the Animal
Health Division including roles in European Key Account Management, Global Brand
Management and Strategic Planning. He went on to support Integration Planning in
the sale of Novartis Animal Health to Eli Lilly & Co, Elanco Animal Health where
he continued as an Operations Consultant in the Elanco Integration Management
Office before joining Stonehaven Consulting AG as Junior Partner in 2015. Oliver
spent the last three years performing a range of consulting studies including
Strategy and M&A.

Oliver has a background in science, having started his career working as a
Biologist for a Scottish aquaculture company and holds a Bachelor of Science
Degree in Marine Science from the University of Cardiff.
‍
Read less

Dr. Scott Carter
Chief Scientific Officer

Animal Health and nutrition expert with 20 years’ experience in Research &
Development.Read more‍

Dr. Scott Carter has twenty years’ experience in Animal Health and Nutrition. He
earned his PhD from North Carolina State University in Nutrition and
Biotechnology with a focus on the production and application of enzymes to
livestock diets to enhance utilization of feed.  His career has been focused on
the application of biotechnology to enhance animal health and performance. He
has extensive experience in the application of enzyme, probiotic, and prebiotic
technologies to farm and companion animals.

Dr. Carter worked as Director of Nutritional Health R&D and Enzymes Global
Marketing at Elanco Animal Health. Prior to this, he held leadership positions
in Sales and Marketing at Alltech and Novus International respectively.

Dr. Carter worked as Director of Business Development Baylor College of Medicine
before taking up his current position as Chief Scientific Officer and Head of
R&D at ANIZOME.

Read less

Joy Nassif
Chief Financial Officer

Financial executive with 20 years’ experience in healthcare and
pharmaceuticals.Read more


Ms. Nassif has over 20 years’ experience in financial and executive management
in the healthcare, diagnostic testing, and pharmaceutical industries. Her career
has included demonstrated ability to maximize return on investment through
aggressive working capital and operating expense management. Additionally, she
has experience in building and operationalizing start-up corporations.  She
currently serves as the Chief Operating Officer of Diversigen, Inc. where she
leads all aspects of the company’s sales, marketing, and operational efforts. 
In the years prior to joining Diversigen, Ms. Nassif held leadership positions
at Quest Diagnostics as Vice President of Clinical Trials, and Vice President of
Anatomic Pathology. During her tenure at Quest Diagnostics, she developed the
strategy for the pharmaceutical division, led the transformation of the
international clinical trials business from loss making to profit, and launched
the first profitable product in cytology for the company. She obtained a Green
Belt in Six Sigma Quality.

Ms. Nassif held the positions of Chief Financial Officer and Chief Operating
Officer of Franklin Heath, Inc. (A Corning Company). She was responsible for all
aspects of operations and administration for this start-up healthcare company.
Additionally, Ms. Nassif was director of Finance for Covance, Inc. working in
its Phase II-III contract research organization. There, she had international
responsibilities for pricing, contracts, revenue recognition, and budgeting.

Ms. Nassif graduated summa cum laude from Kean University with a BS in
Accounting. She is a Certified Public Accountant. In addition to her corporate
positions, she has served on the Board of Advisors for several non-profit groups
and organizations.
‍
Read less

Shawn Davis

BCM Partner Relations

Vice President of Research responsible for business and operational aspects of
research and commercialization at Baylor College of Medicine.Read more

Shawn R. Davis, VP of Research, is responsible for advancing BCM’s strategic
vision for research and commercialization. She oversees the operational and
business aspects of the Research Mission, including all commercialization
activities. She provides proactive leadership and direction for all aspects of
the Research Mission operations and administration, including annual planning,
capital and operating budget management, research space management, research
technology strategy, philanthropy, and affiliate relationships. She oversees
BCM’s strategic relationships with external commercial partners, ensuring an
integrated approach to commercialization aligned to institutional vision.
‍
Read less

Dr. Lucia Martini
Service Manager

Animal physiology and ethology research scientist with expertise in metagenomic
sequencing.Read more

Dr. Lucia Martini is a research scientist with over 12 years’ experience in the
area of translational research and over 5 years as a consultant for the
biomedical industry with hands on experience in pre-clinical and clinical
trials. Dr. Martini earned her Ph.D. from Comenius University, Slovakia in
Animal Physiology and Ethology, a PhD program in conjunction with the National
Institutes of Health, Bethesda, Maryland. Dr. Martini conducted her postdoctoral
research at Cornell University focusing on Nutritional Sciences. Lucia is
Associate Director of Business Development at Diversigen and manager of
metagenomic sequencing services for ANIZOME.
‍
Read less




BOARD OF DIRECTORS

Dr. Adam Kuspa


Senior Vice President and Dean for Research at Baylor College of Medicine with a
personal track-record in genomic research. Read more

Adam Kuspa, PhD, SVP & Dean of Research, is responsible for the development and
execution of BCM’s strategic vision for research and commercialization. He
oversees and allocates institutional resources to support all research centers,
departments, and institutes, faculty recruitment, and commercial endeavors. He
is responsible for maintaining Baylor’s extensive research support
infrastructure including pre-award and compliance functions, a vast animal
program, Advanced Technology Cores, Research IT, the Institute for Clinical and
Translational Research (ICTR) and laboratory safety. He partners with BCM
affiliates toward the advancement of a collaborative research vision. His major
focus is to integrate clinical and translational research across BCM, as well as
to promote the commercial development of the discoveries that result. Dr.
Kuspa’s own federally funded laboratory currently investigates the multifaceted
way that eukaryotic cells kill bacteria.
‍
Read less

Matthias Hofer

Partner at Stonehaven Consulting AG with executive leadership experience in the
Animal Health industry. Read more

Mr. Matthias Hofer is a Partner at Stonehaven Consulting AG. He has over 13
years of experience in Animal Health. He served on the executive committees of
two major Animal Health companies for a total of 7 years. Between 2009 and 2013
he led the global Aqua Health business at Novartis Animal Health (NAH). Later,
he was Global Leader Emerging Business at Elanco and a member of Elanco’s global
executive committee. During 2014 and with Elanco’s intention to buy NAH,
Matthias served as overall pre-merger integration leader on the Novartis side.
In that role, Matthias led a large team and efforts to prepare integration
pre-closing overall including carve-out preparations of operations linked to
Novartis. Matthias is a business leader with broad international experience and
strength in sales, strategy, and execution.
‍
Read less

Dr. Caroline Popper


Chief Executive Officer and Chairman of Diversigen Inc. with 25 years of
hands-on life science operating experience.Read more

Caroline Popper MD MPH is the CEO of Diversigen and the President of BCM
Technologies, the company creation enterprise of Baylor College of Medicine. Dr.
Popper has more than 25 years of hands-on life science operating experience.
Originally an internist and pathologist, she combines her medical and scientific
perspective with knowledge gained from managing a wide spectrum of life sciences
businesses in both Fortune 500 and start-up settings in the US and globally. She
maintains a large venture and private equity network, sits on several company
boards, and speaks internationally on healthcare innovation and value analysis.
Dr. Popper received her medical degree from the University of the Witwatersrand
(South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She
completed her residencies in internal medicine and in pathology at Johns
Hopkins.
‍
Read less


PARTNER WITH US


COMMERCIAL PARTNERSHIPS

ANIZOME’s commercialization plan features establishment of partnerships, joint
ventures, and licensing arrangements with industry to fuel microbiome innovation
needs.


We are also interested in working together with other successful microbiome
companies that have discovery or proprietary assets with potential in animal
health.


If you would like to discuss partnering opportunities, contact us.



ACADEMIC & RESEARCH COLLABORATIONS

ANIZOME is working with academic researchers and institutes to generate samples
from controlled disease cohorts and explore the role of the microbiome. We are
always looking to collaborate and recruit innovation to our platform to help
bridge the gap between research and commercialization.

If you are interested in collaborating, please contact us.


Contact Us


LATEST NEWS


ANIZOME LAUNCHES MICROBIOME DISCOVERY PLATFORM FOR ANIMAL HEALTH AND NUTRITION

23rd May, 2018

ANIZOME, the first company to offer a commercial therapeutic microbiome
discovery platform dedicated to animal health and nutrition, will be launched
today.

Read More


CONTACT US

To contact us, email info@anizome.com or complete the form below.

Name *
Company name *
Email address *
Phone number
Enquiry details *



Thank you! Your information has been received!

Oops! Something went wrong while submitting the form.

ANIZOME LLC
2 Greenway Plaza
Suite 910
Houston
TX 77046 USA

info@anizome.com




© ANIZOME 2018|Terms & Conditions|Acceptable Use Policy|Cookie Policy